Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UFluA Vaccine in Healthy Adults
NCT05155319Phase 1Completed
- Sponsor
- Emergent BioSolutions
- Start
- Dec 2021
- Primary completion
- Oct 2023
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EBS-UFV-001 in influenza (6 cohorts), sponsored by Emergent BioSolutions. Primary endpoints: Safety of the UFluA vaccine at 48 weeks and Local and systemic reactogenicity. Started Dec 2021; status: completed.
02
Drugs
EBS-UFV-001
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05155319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05155319.